Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK256073A · 3 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| GSK256073A tablets + IR niacin tablets | DRUG | single dosing for 4 to 5 sessions |
| GSK256073A tablets | DRUG | - |
Inclusion Criteria: * Adult males between 18 and 55 years of age, inclusive. * Healthy subjects * Body weight \> 50 kg (110 pounds) and body mass index (BMI) between 19 and 31 where: * Subjects with QTc \< 450 msec at screening Exclusion Criteria: * History of significant cardiac arrhythmias * Ac...
GSK256073A is an investigational small molecule being studied in healthy subjects with dyslipidaemias, a condition involving abnormal lipid levels. It is in Phase 1 clinical development for cardiovascular therapeutic use. The drug is not approved and remains in early-stage clinical testing.
GSK256073A is being developed by GSK plc, a pharmaceutical company traded on the London Stock Exchange under the ticker GSK. The company is conducting Phase 1 clinical trials to evaluate the drug's pharmacokinetics and pharmacodynamics in healthy volunteers.
GSK256073A is in Phase 1 clinical development. Three Phase 1 trials have been completed, with a total enrollment of 84 participants. The drug is investigational and has not been approved by regulatory authorities.
GSK256073A has been studied in three completed Phase 1 trials: NCT00488449, which examined pharmacokinetics and pharmacodynamics in 56 healthy volunteers; NCT00551694, a second study in 4 healthy volunteers; and NCT00608699, which assessed the drug's ability to block niacin-induced flushing in 24 male healthy volunteers.
GSK256073A is not niacin, but it is being studied for its potential to block niacin-induced flushing. In clinical trial NCT00608699, researchers evaluated whether GSK256073A could prevent the flushing side effect commonly associated with niacin treatment in healthy volunteers.